The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Camurus ABEU/1/18/1336/002

Main Information

Trade NameBuvidal
Active SubstancesBuprenorphine
Dosage FormProlonged-release solution for injection
Licence HolderCamurus AB
Licence NumberEU/1/18/1336/002

Group Information

ATC CodeN07BC Drugs used in opioid dependence
N07BC01 buprenorphine


License statusAuthorised
Licence Issued20/11/2018
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to special and restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2). This product contains a substance listed in Schedule 2 to the Misuse of Drugs Regulations 2017.
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back